- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Alexion Pharmaceuticals Inc
+ Add to WatchlistALXN:US
99.1700 USD 0.7100 0.71%As of 20:10:00 ET on 05/24/2013.
Snapshot for Alexion Pharmaceuticals Inc (ALXN)
| Open: | 98.8300 | Day's Range: | 98.0450 - 99.7100 | Volume: | 684,979 |
|---|---|---|---|---|---|
| Previous Close: | 99.1700 | 52wk Range: | 81.8200 - 119.5390 | 1-Yr Rtn: | +7.30% |
Key Statistics for ALXN
| Current P/E Ratio (ttm) | 66.8122 |
|---|---|
| Estimated P/E(12/2013) | 33.5828 |
| Relative P/E vs. SPX | 4.1475 |
| Earnings Per Share (USD) (ttm) | 1.4843 |
| Est. EPS (USD) (12/2013) | 2.9530 |
| Est. PEG Ratio | 1.4138 |
| Market Cap (M USD) | 19,358.90 |
| Shares Outstanding (M) | 195.21 |
| 30 Day Average Volume | 1,569,327 |
| Price/Book (mrq) | 9.2551 |
| Price/Sale (ttm) | 15.5701 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/25/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ALXN
Company Profile & Key Executives for ALXN
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, researches and develops proprietary immunoregulatory compounds for the treatment of autoimmune and cardiovascular diseases. The Company develops C5 complement inhibitors and Apogens which are two classes of potential therapeutic compounds designed to selectively target specific disease-causing segments of the immune system.
| Leonard BellCEO/Treasurer/Founder | Vikas SinhaExec VP/CFO |
| David L HallalExec VP/Chief Commercial Ofcr | Stephen P SquintoExec VP/Chief Global Ops Ofcr |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ALXN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page